Richmond Pharmacology is pleased to join the EASL Congress 2026 in Barcelona, Spain, on 27–30 May 2026.

As one of the world’s leading hepatology meetings, the EASL Congress brings together clinicians, researchers, industry experts, and global stakeholders to explore the latest advances in liver disease research, diagnostics, therapeutics, and clinical care.

Representing Richmond Pharmacology:

  • Dr Jörg Taubel, Chief Executive Officer

Our Focus at the Congress

  • Emerging therapies and clinical strategies for liver disease
  • Translation of hepatology research into early‑phase clinical development
  • Biomarker‑driven approaches to trial design and patient selection
  • Evolving regulatory pathways for hepatology therapeutics
  • Collaboration across academia, industry, and global liver health communities

Connect With Us

If you are attending the EASL Congress 2026 and would like to explore collaboration or development opportunities:

📧 fasteranswers@richmondpharmacology.com

Find out more here: EASL Congress 2026 - EASL-The Home of Hepatology.

Latest news

Richmond Pharmacology Appoints Dr Daniel Chapple as Commercial Director

July 13, 2026
Richmond Pharmacology, the London-based contract research organisation and global leader in early phase clinical trials, announces the appointment of Dr Daniel Chapple PhD FCIM as Commercial Director.
Read more

Upcoming Event

ESC Congress 2026

28 - 31 August 2026
Richmond Pharmacology is pleased to attend the ESC Congress 2026 in Munich, Germany, on 28 - 31 August 2026.
View event